Patologia: Carcinoma del pancreas esocrino, Tumori del colon retto, Tumori delle vie biliari
Osservazionale-Sperimentale: Sperimentale
Monocentrico-Multicentrico: Multicentrico
Randomizzato: No
Fase di studio: 1, II
Linee di trattamento: Seconda linea, Terza/N linea
Criteri di inclusione:
The main inclusion criteria include but are not limited to the following:
- Has one of the following cancers:
- Unresectable or metastatic colorectal cancer
- Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
- Advanced and/or unresectable biliary tract cancer (BTC)
- Has received prior therapy for the cancer
- Has recovered from any side effects due to previous cancer treatment.
Criteri di esclusione:
The main exclusion criteria include but are not limited to the following:
- History of severe eye disease
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung diseas.
Trattamento sperimentale:
BIOLOGICAL: Sacituzumab tirumotecan
DRUG: Fluorouracil (5-FU)
DRUG: Leucovorin (LV) or levoleucovorin
DRUG: Rescue medication
DRUG: Supportive care measures
Trattamento di controllo:
-
IRCCS Istituto Nazionale dei Tumori
Via Venezian 1 - 20133 Milano - MI
SC Oncologia Medica 1
Riferimento: Dr. Filippo Pietrantonio
Telefono: 0223903822
Email: filippo.pietrantonio@istitutotumori.mi.it
Numero di iscrizione a registro: 2023-508703-21 - NCT06428409
Data di inserimento: 23.09.2024
Merck Sharp & Dohme LLC
Riferimento: Dr. Info non applicabile
Telefono: 00000
Email: na@na.it
Localita: na